Drugs / Tiragolumab
Trials 65 · started per year
today
1
3
2
5
10
9
7
17
4
7
20172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06760481 | Apr 2025 → Sep 2028 expected | high grade malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05259319 | Dec 2022 → Dec 2024 | head and neck cancer, non-small cell lung carcinoma, renal cell carcinoma, urinary bladder cancer | Centre Georges Francois Leclerc | Unknown | No outcome recorded |
| Phase 1 | NCT04929223 | Oct 2021 → Aug 2030 expected | colorectal cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT04584112 | Sep 2020 → Mar 2023 | triple-negative breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04045028 | Jul 2019 → Mar 2023 | non-Hodgkin lymphoma, plasma cell myeloma | Genentech, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02794571 | May 2016 → Nov 2024 | metastatic neoplasm | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/214 trials · 5 missed | ||||||
| Phase 1/2 | NCT05908786 | Dec 2023 → Aug 2025 | hepatocellular carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT05743504 | Sep 2023 → May 2025 | esophageal squamous cell carcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05459129 | Apr 2023 → Aug 2024 | head and neck squamous cell carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 1/2 | NCT05394337 | Feb 2023 → Dec 2028 expected | metastatic malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05286801 | Nov 2022 → Mar 2030 expected | atypical teratoid rhabdoid tumor, epithelioid sarcoma, high grade malignant neoplasm, kidney medullary carcinoma +1 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05315713 | May 2022 → Jul 2023 | follicular lymphoma | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05251948 | Mar 2022 → Sep 2025 | gastroesophageal cancer | Hoffmann-La Roche | Terminated | Missed primary |
| Phase 1/2 | NCT05116202 | Feb 2022 → Sep 2023 | melanoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 1/2 | NCT04486352 | Oct 2021 → Oct 2026 expected | endometrial cancer | Alliance Foundation Trials, LLC. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04524871 | Nov 2020 → Jul 2027 expected | liver cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03869190 | Jun 2019 → Oct 2025 | urinary bladder cancer, urothelial carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 1/2 | NCT03337698 | Dec 2017 → Oct 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT03281369 | Oct 2017 → Oct 2025 | digestive system carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT03193190 | Jul 2017 → Feb 2025 | pancreatic adenocarcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 235 trials · 2 met primary · 2 missed | ||||||
| Phase 2 | NCT06603818 | Aug 2025 | colorectal cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT07038915 | Jul 2025 | squamous cell lung carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT06328036 | Apr → Jul 2025 | IDH-wildtype glioblastoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT06754501 | Apr 2025 → Jul 2027 expected | cancer | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06784947 | Mar → Sep 2025 overdue | colorectal cancer | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06713798 | Jan → Sep 2025 | lung cancer | Gustave Roussy, Cancer Campus, Grand Paris | Withdrawn | No outcome recorded |
| Phase 2 | NCT06331598 | Nov 2024 → Oct 2028 | cancer | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 2 | NCT06342037 | Jun 2024 → Apr 2026 overdue | breast cancer | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06175390 | Mar 2024 → Aug 2026 overdue | triple-negative breast carcinoma | Institut Curie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06003621 | Dec 2023 → May 2026 overdue | cancer | Omico | Recruiting | No outcome recorded |
| Phase 2 | NCT05798663 | Dec 2023 → Feb 2027 expected | non-small cell lung carcinoma | Alliance Foundation Trials, LLC. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05483400 | Oct 2023 → Sep 2025 overdue | head and neck neoplasm, melanoma | University Medical Center Groningen | Recruiting | No outcome recorded |
| Phase 2 | NCT05715281 | Sep 2023 → Oct 2025 overdue | high grade malignant neoplasm, refractory malignant neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05746481 | Aug 2023 → Aug 2024 | non-small cell lung carcinoma | Liza Villaruz, MD | Terminated | No outcome recorded |
| Phase 2 | NCT05681039 | Jun 2023 → Nov 2026 expected | oral cavity squamous cell carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05825625 | May 2023 → Dec 2026 expected | non-small cell lung carcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05661578 | May 2023 → Dec 2025 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT05805501 | Apr 2023 → Oct 2026 expected | renal cell carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05645692 | Apr 2023 → Dec 2026 expected | urothelial carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05661188 | Feb 2023 → Sep 2026 | anal canal squamous cell carcinoma | Grupo Espanol Multidisciplinario del Cancer Digestivo | Completed | No outcome recorded |
| Phase 2 | NCT05060003 | Nov 2022 → Nov 2023 | melanoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT05009069 | Mar 2022 → Nov 2023 overdue | rectal cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04958811 | Dec 2021 → Nov 2026 expected | non-small cell lung carcinoma | Georgetown University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04308785 | Dec 2021 → Jul 2023 | small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 2 | NCT05034055 | Dec 2021 → Dec 2023 | non-small cell lung carcinoma | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT04933227 | Aug 2021 → Nov 2023 | gastric cancer, gastroesophageal junction adenocarcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 2 | NCT04832854 | Apr 2021 → Mar 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 2 | NCT04665843 | Mar 2021 → Sep 2023 | head and neck squamous cell carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT04632992 | Jan 2021 → Dec 2023 | cancer of unknown primary site | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04300647 | Jun 2020 → Dec 2021 | cervical cancer | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT03977467 | Aug 2019 → Aug 2024 | non-small cell lung carcinoma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03708224 | Mar 2019 → Jun 2028 expected | head and neck cancer, squamous cell carcinoma | Alain Algazi | Recruiting | No outcome recorded |
| Phase 2 | NCT03784326 | Feb 2019 → Dec 2026 expected | esophageal adenocarcinoma, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03554083 | Oct 2018 → Apr 2025 | cutaneous melanoma | Mayo Clinic | Completed | Met primary |
| Phase 2 | NCT03563716 | Aug 2018 → Jun 2019 | non-small cell lung carcinoma | Genentech, Inc. | Completed | Met primary |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT04619797 | Dec 2020 → Apr 2024 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 39 trials · 1 met primary · 3 missed | ||||||
| Phase 3 | NCT06267001 | Mar 2024 → Dec 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT05904886 | Sep 2023 → May 2025 overdue | hepatocellular carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05862285 | Jun 2023 → Mar 2033 expected | cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT04665856 | Dec 2020 → Aug 2023 | small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04540211 | Oct 2020 → Feb 2023 | esophageal cancer | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT04543617 | Sep 2020 → Jul 2026 | esophageal squamous cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04513925 | Aug 2020 → May 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT04294810 | Mar 2020 → Dec 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT04256421 | Feb 2020 → Sep 2022 | small cell lung carcinoma | Hoffmann-La Roche | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2024-11-26 | Hoffmann-La Roche | Results Roche reports update on Phase III SKYSCRAPER-01 study results roche.com ↗
The study did not reach the primary endpoint of overall survival at the final analysis. |
| 2024-11-25 | Genentech, Inc. | Results Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results gene.com ↗
The study did not reach the primary endpoint of overall survival at the final analysis. |
| 2024-07-04 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer roche.com ↗
The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy in both PFS and OS compared to the comparator arm in the intent-to-treat population, which includes the phase II and phase III cohorts. |
| 2024-07-03 | Genentech, Inc. | Results Genentech Provides Update on Phase II/III Skyscraper-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer gene.com ↗
The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy in both PFS and OS compared to the comparator arm in the intent-to-treat population, which includes Phase II and Phase III cohorts. |
| 2023-08-23 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer roche.com ↗
The data showed that tiragolumab plus Tecentriq was well-tolerated and no new safety signals were identified when adding tiragolumab to Tecentriq. |
| 2023-08-22 | Genentech, Inc. | Results Genentech Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer gene.com ↗
The data showed that tiragolumab plus Tecentriq was well-tolerated and no new safety signals were identified when adding tiragolumab to Tecentriq. |
| 2022-05-11 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer roche.com ↗
The study did not meet its co-primary endpoint of progression-free survival. |
| 2022-05-11 | Chugai Pharmaceutical | Results Roche Announces Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer chugai-pharm.co.jp ↗
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche issued a press release regarding interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer of the investigational anti-TIGIT immunotherapy tiragolumab. |
| 2022-05-10 | Genentech, Inc. | Results Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer gene.com ↗
The study did not meet its co-primary endpoint of progression-free survival. |
| 2022-03-30 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer roche.com ↗ |
| 2022-03-29 | Genentech, Inc. | Results Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer gene.com ↗
SKYSCRAPER-02, the first randomized study of tiragolumab in extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival |
| 2021-12-10 | Hoffmann-La Roche | Results New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq roche.com ↗ |
| 2021-12-10 | Genentech, Inc. | Results New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq gene.com ↗
After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free survival improvement for the combination compared with Tecentriq alone |
| 2021-01-05 | Hoffmann-La Roche | Regulatory Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer roche.com ↗
Tiragolumab is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation (BTD) and marks the 37th BTD for Roche’s portfolio of medicines |
| 2021-01-04 | Genentech, Inc. | Regulatory Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer gene.com ↗
Tiragolumab is the first anti-TIGIT molecule to be granted BTD from the FDA, and the designation is based on randomized data from the Phase II CITYSCAPE trial. |
| 2020-05-14 | Hoffmann-La Roche | Results Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO roche.com ↗
Phase II CITYSCAPE trial shows promising results adding tiragolumab to Tecentriq in people with PD-L1-positive metastatic non-small cell lung cancer |
| 2020-05-13 | Genentech, Inc. | Results Genentech to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO gene.com ↗
“We are pleased to share these first randomized anti-TIGIT results, showing that tiragolumab, our novel cancer immunotherapy, has encouraging efficacy and safety in combination with Tecentriq,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. |
All press releases naming this drug 17 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 68 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tiragolumab | “All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy” NCT05661188 ↗64“four cycles of 1200 mg of atezolizumab (Tecentriq®, Roche) and 600 mg of Tiragolumab (Roche) every 3 weeks” NCT06175390 ↗ |
| Known as | MTIG-7192A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298050 ↗ |
| Known as | RG-6058 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298050 ↗ |
| Known as | RO-7092284 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298050 ↗ |
| Known as | Tira | “Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated...” NCT03869190 ↗1“This study evaluated the safety and efficacy of atezolizumab (Atezo) with or without tiragolumab (Tira) after nCRT in patients with LARC.” PMID 41529226 ↗ Jan 2026 |
| Action | Inhibit | “that blocks the binding of TIGIT to CD155” PMID 38105505 ↗ Jan 2024 |
| Modality | Monoclonal antibody | “Tiragolumab is a first-in-class, fully human IgG1/kappa anti-TIGIT monoclonal antibody” PMID 38105505 ↗ Jan 2024 |
| Route | Intravenous | “Tiragolumab will be given via IV infusion” NCT02794571 ↗ |
| Target | TIGIT | “Tiragolumab is a first-in-class, fully human IgG1/kappa anti-TIGIT monoclonal antibody that blocks the binding of TIGIT to CD155” PMID 38105505 ↗ Jan 2024 |